Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217524 · ClinicalTrials.gov registry record
Samsung Galaxy Watch Body Composition Study
A clinical trial, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- 110
- Enrollment target
NCT05217524: Completed study, sponsored by Pennington Biomedical Research Center.
NCT05217524 is a clinical trial that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05217524 has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
The aim of this study is to acquire impedance measurements of the adult human body with a novel bioimpedance device housed inside a watch case and to compare derived estimates of body composition measured by dual-energy x-ray absorptiometry (DXA) and other bioimpedance analysis (BIA) systems.
Primary Outcome
Referenced against DXA
Interventions
- DEVICE Galaxy BIA watch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2022-01-01 |
What the finished NCT05217524 record still lists
NCT05217524 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Galaxy BIA watch is the first listed.
NCT05217524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05217524 about?
NCT05217524 is a clinical study titled "Samsung Galaxy Watch Body Composition Study". The aim of this study is to acquire impedance measurements of the adult human body with a novel bioimpedance device housed inside a watch case and to compare derived estimates of body composition measured by dual-energy x-ray absorptiometry (DXA) and other bioimpedance analysis (BIA) systems.
What is the current status of trial NCT05217524?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2021-05-01. Estimated completion is 2022-01-01.
What interventions are being tested in trial NCT05217524?
The interventions under investigation include: Galaxy BIA watch (DEVICE).
Who is sponsoring clinical trial NCT05217524?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI